# Red Queen Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/red-queen-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.redqueentx.com
- Total disclosed funding: $5M
- Latest round: Series A (Oct 13, 2021)
- Investors on record: 1

## About

Red Queen Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative antiviral therapeutics using a proprietary stapled lipopeptide platform technology to combat viral infections.Founded in Cambridge, US, Red Queen Therapeutics, Inc. specializes in antiviral therapeutics. The company has undergone no major pivots in its business strategy. It raised USD 5.00 mn in Series A funding in October 2021 from Apple Tree Partners, marking its total amount raised at USD 5.00 mn and its current valuation at USD 51.51 mn.Red Queen Therapeutics specializes in the development of antiviral therapeutics utilizing a proprietary stapled lipopeptide platform technology. This platform is designed to block virus-cell fusion, effectively preventing the entry of enveloped viruses into human cells, thereby addressing a broad spectrum of virus-borne illnesses, such as COVID-19, influenza, respiratory syncytial virus (RSV), and others. Their lead product, RQ-01, has been evaluated in Phase 1 clinical trials and has demonstrated promising results in terms of safety and accelerated viral clearance in patients with COVID-19. The therapies are intended for use in various geographical markets, particularly in North America and Europe, and are aimed at healthcare providers, hospitals, and clinics that cater to patients at risk of severe viral infections. The products can be administered via multiple routes, including intranasal, inhalation, or injection, enhancing accessibility for end users and healthcare professionals.Red Queen Therapeutics' revenue model is primarily structured around partnerships and direct sales of their antiviral products to healthcare providers and institutions. The company engages in clinical trial collaborations and licensing agreements, which facilitate the development and commercialization of its therapeutic agents. Revenue generation may involve both upfront payments and milestone-based royalties associated with the successful progression of its products through clinical stages. The flagship product, RQ-01, alongside other pipeline candidates, is positioned for eventual market entry, with pricing strategies potentially reflecting the innovative nature of its lipopeptide therapies. The transactional framework is designed to meet the needs of hospitals and clinics, ensuring that healthcare professionals can access these therapeutics as they advance through regulatory approval and into commercial availability.In October 2021, Red Queen Therapeutics, Inc. raised USD 5.00 mn in Series A funding from new investor Apple Tree Partners. The company plans to use this funding to accelerate its development activities and broaden its operational scope. Future growth initiatives include the development of new antiviral products and expansion into additional markets, particularly focusing on regions in North America and Europe by the end of 2023.

## Funding rounds

- Series A, Oct 13, 2021, $5M — Apple Tree Partners

## Investors

- Apple Tree Partners (https://capitalatlas.ai/funds/apple-tree-partners) — Series A